Patent Foramen Ovale and Oxygenation in Patients with Cystic Fibrosis
Respiration · 2024
DOI: 10.1159/000541892 ↗Kurz gefasst
Fachartikel in der Zeitschrift Respiration, 2024. Verfasst von Haley Belt und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Foramen Ovale, Patent, Cystic Fibrosis, Hypoxia, Oxygen Inhalation Therapy. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Introduction
Patent foramen ovale (PFO) affects about 25% of the population. We studied outcomes in cystic fibrosis (CF).
Methods
We conducted a case-control study of patients with CF (PwCF) and age- and sex-matched controls who underwent agitated saline contrast (bubble) echocardiography, 1998–2020. We assessed PFO impacts using linear, logistic, quasi-Poisson, and Cox proportional hazards models.
Result
Fifty-nine of 64 PwCF and 88 of 93 controls underwent bubble studies to investigate unexplained hypoxemia or dyspnea. PwCF had higher mean pulmonary artery pressure (PAP: 6.9 mm Hg, 95% confidence interval [CI] = 2.35–11.4), reduced tricuspid annular plane systolic excursion (TAPSE: −3.78 mm, CI = −5.64 to −1.93) and similar right ventricular diastolic sizes. Without hypoxemia, the PFO incidence was similar between PwCF and controls; with hypoxemia, PFO was more common in CF (odds ratio = 5.00, CI = 1.32–19.0). In CF, oxygen supplementation occurred at a percent-predicted forced expiratory volume in 1 s (FEV1%), 22.5 points higher with PFO. Adjusted for FEV1%, PFO was associated with 0.59 more prior-year pulmonary exacerbations (CI = 0.20–0.98) and shorter time to next exacerbation (hazard ratio = 1.86, CI = 1.06–3.26). Associations between PFO and hypoxemia or exacerbations were insensitive to PAP, TAPSE, and CF transmembrane regulator protein modulator treatments. PFO was not associated with CF time to death or lung transplantation (median 1.87 years) adjusted for age, sex, FEV1%, and prior-year exacerbation counts.
Conclusion
PFO in CF is associated with hypoxemia at higher FEV1% and more pulmonary exacerbations but not survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
- Division of Cardiovascular Medicine, University of Utah, Salt Lake City, Utah, USA.
- The Division of Respiratory, Critical Care and Occupational Pulmonary Medicine, University of Utah, Salt Lake City, Utah, USA.
- The Adult Cystic Fibrosis Center, University of Utah, Salt Lake City, Utah, USA.
- The Center for Quantitative Biology, University of Utah, Salt Lake City, Utah, USA.
Förderung
- NHLBI NIH HHS
Zitieren
APA
Belt, H., Enakpene, E. O., Jensen, J. L., Moe, A. P., Carveth, H., Cahill, B. C., Hatton, N., Liou, T. G., & Tandar, A. (2024). Patent Foramen Ovale and Oxygenation in Patients with Cystic Fibrosis. Respiration. https://doi.org/10.1159/000541892
Vancouver
Belt H, Enakpene EO, Jensen JL, Moe AP, Carveth H, Cahill BC, et al. Patent Foramen Ovale and Oxygenation in Patients with Cystic Fibrosis. Respiration. 2024. doi:10.1159/000541892
BibTeX
@article{Belt2024,
author = {Belt, Haley and Enakpene, Evbu O and Jensen, Judy L and Moe, Alice P and Carveth, Holly and Cahill, Barbara C and Hatton, Nathan and Liou, Theodore G and Tandar, Anwar},
title = {Patent Foramen Ovale and Oxygenation in Patients with Cystic Fibrosis},
journal = {Respiration},
year = {2024},
doi = {10.1159/000541892}
}
EUVIMED